Advanced Recomp Stack
The Advanced Recomp Stack is a combination of three research peptides: retatrutide, CJC-1295 (No DAC) and ipamorelin, used as separate vials or with the last two pre-blended. It is discussed for fat loss with lean-mass support, and no published human trial has tested all three together.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
At a glance
- Body composition
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- Sources differ. See the source
How much to draw
Full calculator →The reference does not report a single injectable amount for Advanced Recomp Stack, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Advanced Recomp Stack or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Retatrutide: 2 mg/week (initiation, weeks 1-4) escalating to 12 mg/week (maximum, weeks 17-20+); CJC-1295 (No DAC): 100-200 mcg, 1-2x daily; Ipamorelin: 100-200 mcg, 1-2x daily | Retatrutide: once weekly; CJC-1295 and ipamorelin: 1-2x daily (5-on / 2-off rhythm)Standard cycle 12-16 weeks; Extended cycle 16-24 weeks; Continuous retatrutide + cycled CJC/Ipa (12 weeks on / 4 weeks off). CJC/Ipa cycled 12 weeks on / 4 weeks off; retatrutide can continue. | subcutaneous | peptidedosingprotocols.comWhat it saysHide[Source: peptidedosingprotocols.com] |
- Retatrutide: once weekly; CJC-1295 and ipamorelin: 1-2x daily (5-on / 2-off rhythm)Standard cycle 12-16 weeks; Extended cycle 16-24 weeks; Continuous retatrutide + cycled CJC/Ipa (12 weeks on / 4 weeks off). CJC/Ipa cycled 12 weeks on / 4 weeks off; retatrutide can continue.
- subcutaneous
- peptidedosingprotocols.com
What it saysHide
[Source: peptidedosingprotocols.com]
- Retatrutide: 5 mg vial + 1 mL BAC water = 5 mg/mL; 10 mg vial + 2 mL BAC water = 5 mg/mL; 10 mg vial + 1 mL BAC water = 10 mg/mL; 20 mg vial + 2 mL BAC water = 10 mg/mL. Volumes over 1.0 mL need a larger syringe or a split injection at two sites. CJC-1295 (No DAC): 2 mg vial + 1 mL BAC water = 2,000 mcg/mL; 5 mg vial + 2 mL BAC water = 2,500 mcg/mL; 5 mg vial + 2.5 mL BAC water = 2,000 mcg/mL. Ipamorelin: same math as CJC-1295. Pre-blended CJC/Ipa combo vial (10 mg = 5 mg CJC + 5 mg ipamorelin): reconstitute with 2 mL BAC water for 2,500 mcg/mL per peptide; 8 units (0.08 mL) = ~200 mcg of each. Label every vial with compound name, concentration, and reconstitution date. Retatrutide is dosed in mg; CJC/Ipa in mcg, a 1,000x difference. Use U-100 insulin syringes.
We have not published an audit on Advanced Recomp Stack. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Retatrutide lowers appetite, slows digestion and prompts the liver to burn stored fat. CJC-1295 (No DAC) and ipamorelin each prompt the pituitary gland to release a pulse of growth hormone, which is meant to help hold on to lean tissue during a calorie deficit. Researchers link this to retatrutide acting on the GLP-1, GIP and glucagon receptors, and the other two acting on the GHRH receptor and the ghrelin receptor (GHS-R1a). The combination comes from community use, and no published human trial has tested all three together.
Multi-compound stack targeting body composition; components and mechanism per source.
Reported side effects
Seen in studies: the source gives rates for retatrutide of nausea 38-43% and diarrhea 33-35%. It also describes dysesthesia, an unusual tingling or burning feeling in the skin, at higher doses. No clinical trial has tested all three compounds together.
Reported by users: this stack comes from community use. The source lists injection-site reactions and mild water retention from CJC-1295 and ipamorelin. It also flags mix-ups between mg and mcg labels, a 1,000x difference, as the most common dosing error with this stack.
Not ruled out: heart rate changes from retatrutide, blood pressure changes with weight loss, and glucose readings that are hard to interpret because the compounds can pull them in different directions. The source lists severe abdominal pain, persistent vomiting, rapid swelling, chest pain, shortness of breath, fainting and allergic symptoms as needing immediate medical review.
Who should avoid it
People with diabetes or on diabetes medicines: listed as a point to discuss with a clinician, and the source notes the stack can pull glucose readings in different directions.
People with a personal or family history of thyroid cancer, or a history of MEN2: listed as a caution in the reference library, with no reason given.
People with a history of gallbladder problems or pancreatitis: listed as a caution in the reference library, with no reason given.
People with sleep apnea, edema or kidney disease: listed as a caution in the reference library, with no reason given.
People with a cancer history: listed as a caution in the reference library, with no reason given.
Athletes in tested sport: WADA prohibits CJC-1295 and ipamorelin.
What gets monitored
IGF-1 (follow-up); HbA1c (baseline); Fasting glucose (follow-up); Comprehensive metabolic panel / CMP, kidney function, liver enzymes, electrolytes, glucose (baseline); Lipid panel (follow-up); Blood pressure and resting heart rate (follow-up). Re-check metabolic markers and IGF-1 after 6-8 weeks. For longer protocols, review metabolic, IGF-1, kidney, liver, and cardiovascular trends every 3 months with a clinician. (reported by peptidedosingprotocols.com)
Common questions
What is the Advanced Recomp Stack?
It is a combination of three research peptides: retatrutide, CJC-1295 (No DAC) and ipamorelin. Retatrutide is there for fat loss, and the other two raise growth hormone with the aim of supporting lean tissue during a calorie deficit. No published human trial has tested all three together.
Can you stack retatrutide with CJC-1295 and ipamorelin together?
The source describes the pairing as pharmacologically rational, because the compounds act on different receptor systems with no overlap. Retatrutide acts on metabolic receptors, while CJC-1295 and ipamorelin act on growth-hormone receptors. The combination comes from community use, not from a clinical trial.
How is the Advanced Recomp Stack dosed?
Reported amounts and schedules for Advanced Recomp Stack differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
Should I use a pre-blended CJC + ipamorelin vial or separate vials?
Community reports say most users choose the pre-blended CJC-1295 and ipamorelin vial, because it means two vials to reconstitute instead of three and fixes a 1:1 ratio. Separate vials are described as the option for running one peptide higher than the other. Retatrutide is described as always kept in its own vial.
How do you reconstitute the Advanced Recomp Stack?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Why use CJC-1295 without DAC instead of the with-DAC version?
The No DAC version produces short growth hormone pulses that rise and fall, which matches the body's natural rhythm. The with-DAC version keeps growth hormone raised for days. The source says the stack is built around natural-style pulses and that the No DAC version is easier to adjust.
How long should you run the Advanced Recomp Stack?
Sources describe standard cycles of 12-16 weeks and extended cycles of 16-24 weeks. CJC-1295 and ipamorelin are usually described as 12 weeks on and 4 weeks off, to limit receptor desensitization, meaning receptors becoming less responsive over time. Retatrutide is described as able to continue through that off period.
Is the Advanced Recomp Stack safe? What are the main risks?
Its safety is not established, because no clinical trial has tested all three together. The source names retatrutide's gut side effects (nausea 38-43%, diarrhea 33-35%) and dysesthesia, a tingling or burning skin feeling at higher doses, as the biggest known risks, with injection-site reactions and mild water retention from the other two. It adds that retatrutide and growth hormone push insulin sensitivity in opposite directions, which it flags for people with pre-diabetes or insulin resistance.
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
Sermorelin is a lab-made peptide that copies the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It has been studied in the growth hormone system, including FDA-era trials as a diagnostic agent and as a treatment for growth hormone deficiency in children.
This is a combination of two growth hormone compounds sold in a single vial: tesamorelin, a synthetic copy of growth hormone-releasing hormone, and ipamorelin, a ghrelin mimic that acts as a growth hormone secretagogue. It is sold for research use and is studied in the context of the growth hormone system, visceral fat and recovery.
Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.
MOTS-c is a short chain of 16 amino acids that cells build from mitochondrial DNA rather than from the DNA in the nucleus. Most of what is known about it comes from cell and animal work on metabolism, exercise capacity and insulin sensitivity.
Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.